UroGen Pharma Ltd. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Arie Belldegrun, M.D.

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Arie Belldegrun, M.D.”): 23,369,726 for, 4,959,968 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 2,636,797 for, 1,429,400 against, 3,947 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Cynthia M. Butitta

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Cynthia M. Butitta”): 26,378,838 for, 1,940,273 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 4,035,998 for, 30,200 against, 3,947 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Daniel G. Wildman

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Daniel G. Wildman”): 27,862,621 for, 453,366 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 4,066,197 for, 1 against, 3,947 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Elizabeth Barrett

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Elizabeth Barrett”): 25,942,072 for, 2,389,232 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 4,035,998 for, 30,200 against, 3,947 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: James A. Robinson, Jr.

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: James A. Robinson, Jr.”): 27,918,601 for, 407,390 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 4,062,331 for, 3,867 against, 3,947 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Leana S. Wen, M.D., M.Sc.

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Leana S. Wen, M.D., M.Sc.”): 26,667,146 for, 1,652,270 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 3,743,693 for, 322,504 against, 3,947 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Stuart Holden, M.D.

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Stuart Holden, M.D.”): 26,641,539 for, 1,687,876 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 4,035,999 for, 30,199 against, 3,947 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Arie Belldegrun, M.D.

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Arie Belldegrun, M.D.”): 19,945,910 for, 1,978,014 withheld, per its Form 8-K filed August 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 736,064 for, 743,935 withheld.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Cynthia M. Butitta

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Cynthia M. Butitta”): 21,606,978 for, 316,947 withheld, per its Form 8-K filed August 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 1,475,027 for, 4,972 withheld.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Daniel G. Wildman

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Daniel G. Wildman”): 21,700,880 for, 223,045 withheld, per its Form 8-K filed August 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 1,475,196 for, 4,803 withheld.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Elizabeth Barrett

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Elizabeth Barrett”): 19,767,638 for, 2,156,287 withheld, per its Form 8-K filed August 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 1,475,027 for, 4,972 withheld.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: James A. Robinson, Jr.

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: James A. Robinson, Jr.”): 21,685,524 for, 238,401 withheld, per its Form 8-K filed August 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 1,471,364 for, 8,635 withheld.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Leana S. Wen, M.D., M.Sc.

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Leana S. Wen, M.D., M.Sc.”): 21,231,727 for, 692,198 withheld, per its Form 8-K filed August 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 1,423,014 for, 56,985 withheld.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Stuart Holden, M.D.

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Stuart Holden, M.D.”): 21,653,905 for, 270,020 withheld, per its Form 8-K filed August 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The shareholders elected the following seven individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 1,475,027 for, 4,972 withheld.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE COMPANY'S 2017 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF ORDINARY SHARES AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 1,000,000 SHARES.

UroGen Pharma Ltd.’s own tally for this item (“4. 2017 Equity Incentive Plan”): 25,204,644 for, 3,058,912 against — passed, per its Form 8-K filed June 23, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The shareholders approved the 2017 Amended Plan.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 3,118,862 for, 947,336 against, 3,947 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: TO APPROVE AMENDMENTS TO THE COMPANY'S 2017 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE NUMBER OF ORDINARY SHARES AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 2,750,000 SHARES.

UroGen Pharma Ltd.’s own tally for this item (“3. 2017 Amended Plan”): 18,403,175 for, 2,777,281 against — passed, per its Form 8-K filed August 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The shareholders approved the 2017 Amended Plan.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 1,471,364 for, 3,832 against, 4,803 abstained.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.

UroGen Pharma Ltd.’s own tally for this item (“5. Advisory vote on the compensation of the Company ' s named executive officers”): 25,125,846 for, 3,186,040 against — passed, per its Form 8-K filed June 23, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “On an advisory basis, the shareholders approved the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 47 managers: 4,066,193 for, 5 against, 3,947 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 168 managers: 17,394,101 for, 2,887,115 against, 1,923,410 withheld, 2,000 not voted, 10,832 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 34 managers: 1 for, 4,803 abstained, 1,475,195 1 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 120 managers: 20,435 for, 168 against, 18,064,452 withheld, 495,606 abstained, 13,301,429 1 year, 1,000 unknown, 246 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.

UroGen Pharma Ltd.’s own tally for this item (“4. Advisory vote on the compensation of the Company ' s named executive officers”): 18,852,928 for, 2,217,830 against — passed, per its Form 8-K filed August 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “On an advisory basis, the shareholders approved the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 31 managers: 1,445,215 for, 3,832 against, 4,803 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 106 managers: 8,934,294 for, 1,241,081 against, 102,837 withheld, 495,606 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR AND OFFICER COMPENSATION POLICY IN RELATION TO DIRECTORS' AND OFFICERS' INSURANCE.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 47 managers: 4,066,195 for, 3 against, 3,947 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 3 managers: 723,407 for, 770,908 against.

Description as filed by funds: TO APPROVE AMENDMENTS TO THE COMPANY'S 2024 NON-EMPLOYEE DIRECTOR AND OFFICER COMPENSATION POLICY TO, AMONG OTHER THINGS, INCREASE THE EQUITY COMPENSATION PAYABLE TO OUR EXECUTIVE OFFICERS AND NON-EMPLOYEE DIRECTORS.

UroGen Pharma Ltd.’s own tally for this item (“2. Amended and Restated Director and Officer Compensation Policy”): 17,894,986 for, 3,295,431 against — passed, per its Form 8-K filed August 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The shareholders approved the Compensation Policy.”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 34 managers: 1,417,570 for, 57,626 against, 4,803 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 3 managers: 1,167,490 for, 261 against.

Description as filed by funds: To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company's auditor until the Company's 2027 annual meeting of shareholders.

UroGen Pharma Ltd.’s own tally for this item (“6. E ngagement of PricewaterhouseCoopers LLP as the Company's independent auditor”): 36,778,509 for, 90,799 against — passed, per its Form 8-K filed June 23, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The shareholders approved the engagement of PricewaterhouseCoopers LLP as the Company's independent auditor until the Company's 2027 annual meeting of shareholders.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 4,066,198 for, 3,947 abstained.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company's auditor until the Company's 2026 annual meeting of shareholders.

UroGen Pharma Ltd.’s own tally for this item (“6. Engagement of PricewaterhouseCoopers LLP as independent auditor”): 32,922,800 for, 136,141 against — passed, per its Form 8-K filed August 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The shareholders approved the engagement of PricewaterhouseCoopers LLP as the Company's independent auditor until the Company's 2026 annual meeting of shareholders.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 1,475,027 for, 169 against, 4,803 abstained.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE ARTICLES OF ASSOCIATION OF THE COMPANY TO, AMONG OTHER THINGS, TIE ELIGIBILITY FOR SHAREHOLDER PROPOSALS TO THE REQUIREMENTS UNDER THE ISRAELI COMPANIES LAW.

UroGen Pharma Ltd.’s own tally for this item (“2. Amended and Restated Articles of Association”): 19,306,222 for, 9,007,528 against — passed, per its Form 8-K filed June 23, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The shareholders approved the Amended and Restated Articles.”
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of UroGen Pharma Ltd.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “To approve the amendment and restatement of the Artides of Association of the Company to, among other things, tie ellgibility for shareholder proposals to the requirements under the Israeli Companies Law.” (10 managers, 406,946 for, 3,947 abstained).

The 41 asset managers below reported 1,813,722 for, 1,845,530 against.

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.